All In Biotech

NDA 210166 · Takeda Pharms USA

Motegrity

Prucalopride Succinate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Jul 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Dec 14, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

65

22 Phase 3, 3 recruiting

FAERS reports

2,370

1,072 serious, 57 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 17, 2025.

MOTEGRITY ® is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. MOTEGRITY is a serotonin-4 (5-HT 4 ) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults. ( 1 )

Mechanism: Prucalopride, a selective serotonin type 4 (5-HT 4 ) receptor agonist, is a gastrointestinal (GI) prokinetic agent that stimulates colonic peristalsis (high-amplitude propagating contractions [HAPCs]), which increases bowel motility. Prucalopride was devoid of effects mediated via 5-HT 2A , 5-HT 2B , 5-HT 3 , motilin or CCK-A receptors in vitro at concentrations exceeding 5-HT 4 receptor affinity by 150-fold or greater. In isolated GI tissues from various animal species, prucalopride facilitated acetylcholine release to enhance the amplitude of contractions and stimulate peristalsis. In rats...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • MOTEGRITY · PRUCALOPRIDE SUCCINATE EQ 2MG BASE · TABLET, ORAL · Prescription · TE AB
  • MOTEGRITY · PRUCALOPRIDE SUCCINATE EQ 1MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Prucalopride" as an intervention, any sponsor and status, largest first.

All 65 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective275
  • headache248
  • nausea201
  • diarrhoea185
  • no adverse event175
  • off label use174
  • fatigue144
  • constipation143
  • inability to afford medication136
  • dizziness127
  • product use issue116
  • insurance issue109

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20112
20123
20133
20147
201518
201612
201721
201822
2019228
2020279
2021347
2022284
2023288
2024317
2025297
2026241

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Motegrity (Prucalopride Succinate)

2024 spending

$70.7M

Beneficiaries

21,866

91,612 claims

Per beneficiary

$3,232

$17.43 per unit

View as table
YearSpending
2020$22,558,033
2021$33,358,371
2022$48,695,095
2023$61,916,752
2024$70,660,851

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 99 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.